Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:31:03 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Bioharvest Sciences Inc
Symbol BHSC
Shares Issued 478,688,168
Close 2023-12-08 C$ 0.20
Market Cap C$ 95,737,634
Recent Sedar+ Documents

Bioharvest Sciences grants 20-cent options

2023-12-08 18:55 ET - News Release

Subject: Release/News Attached Word Document File: '\\swfile\EmailIn\20231208 155117 Attachment 120823 BHSC NR Stock and warrant issuance approved_forStockwatch.docx' CSE:BHSC - FSE:8MV - OTC: CNVCF OFSE:8MV NR: 120823-1 BIOHARVEST SCIENCES INC. ANNOUNCES GRANT OF STOCK OPTIONS AND ISSUANCE OF WARRANTS VANCOUVER, CANADA, and REHOVOT, ISRAEL, December 8, 2023 -BioHarvest Sciences Inc. ("BioHarvest" or the "Company") (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) announces that it has granted 1,287,500 incentive stock options to employees and 1,675,000 to consultants. The stock options granted are exercisable to purchase a common share of the Company at a price of $.20 per share for a term of 10 years and will vest as follow: Amount of Stock Options Granted Vesting Terms 2,262,500 Vesting Quarterly over a 3-year period 575,000 Vesting Quarterly over a 2-year period 100,000 Vesting quarterly over a 1-year period 25,000 Vesting after 3 months In addition, subject to the approval of the Canadian Securities Exchange, the Company is issuing 2,274,500 warrants to a consultant in accordance with their agreement. The warrants will be valid until Oct 25, 2025, and can be exercised to acquire a common share at a price $0.30 per share. About BioHarvest Sciences Inc. BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. BioHarvest is currently focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions, within two major business verticals - nutraceutical health and wellness products such as dietary supplements, and development of plant cell-based Active Pharmaceutical Ingredients (API's) that focus on specific medical indications. Visit: www.bioharvest.com. BioHarvest Sciences Inc. Ilan Sobel, Chief Executive Officer For further information, please contact: Dave Ryan, VP Investor Relations & Director Phone: 1 (604) 622-1186 Email: dave@bioharvest.com Forward-Looking Statements Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

© 2026 Canjex Publishing Ltd. All rights reserved.